Johnson & Johnson (JNJ)

122.04
NYSE : Health Technology
Prev Close 122.04
Day Low/High 0.00 / 0.00
52 Wk Low/High 118.62 / 148.32
Avg Volume 6.43M
Exchange NYSE
Shares Outstanding 2.68B
Market Cap 328.75B
EPS 0.50
P/E Ratio 266.46
Div & Yield 3.60 (2.82%)

Latest News

Global Gloom: Cramer's 'Mad Money' Recap (Monday 6/18/18)

Global Gloom: Cramer's 'Mad Money' Recap (Monday 6/18/18)

Jim Cramer says we need stocks that are in sync with the global gloom and can be bought when we feel gloomy, which is pretty much every day.

12 Stocks That Make Up the GLUM Index

12 Stocks That Make Up the GLUM Index

Here is a new index for all you traders out there to follow, compliments of TheStreet's founder Jim Cramer. Welcome to the GLUM Index.

3 Great Stocks for Retirees to Own

3 Great Stocks for Retirees to Own

Looking for stocks with a steady stream of income? Check these three names out from TheStreet.

Jim Cramer: A GLUM Index For Gloomy Markets

Jim Cramer: A GLUM Index For Gloomy Markets

Taking the measure of what's keeping the markets in the dumps.

FDA Approves The Next Generation Of Customized LASIK Treatment With IDESIGN Refractive Studio

FDA Approves The Next Generation Of Customized LASIK Treatment With IDESIGN Refractive Studio

Next generation LASIK platform that measures the eye inside and out to enable highly precise personalized vision correction

Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs

Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs

The latest announcement from the U.S. Trade Representative's office is chilling reading for free trade supporters.

Kyros Law Is Investigating Claims On Behalf Of Invokana Users: 1,100 Invokana Lawsuits Alleging Diabetic Ketoacidosis, Kidney Injury, Amputations And Heart Complications Filed.

Kyros Law Is Investigating Claims On Behalf Of Invokana Users: 1,100 Invokana Lawsuits Alleging Diabetic Ketoacidosis, Kidney Injury, Amputations And Heart Complications Filed.

BOSTON, June 14, 2018 /PRNewswire/ -- Kyros Law Offices is alerting individuals that have suffered serious side effects from taking Invokana that it is investigating filing legal claims seeking compensation for their injuries.

Latest Reasons to Avoid Alzheimer's Plays

Latest Reasons to Avoid Alzheimer's Plays

Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.

Peace Hopes Weigh on Defense Stocks

Shares of defense stocks slide after Trump meets Kim.

New Rules of the Road: Cramer's 'Mad Money' Recap (Thursday 6/7/18)

New Rules of the Road: Cramer's 'Mad Money' Recap (Thursday 6/7/18)

Jim Cramer's new rules of the road will help investors stay on course and avoid common mistakes.

Sanofi, Merck and J&J Tout Lower Drug Prices

Sanofi, Merck and J&J Tout Lower Drug Prices

While a handful of drug companies say their average net prices have dropped, FDA Commissioner Scott Gottlieb announces a plan to encourage drug competition in the face of monopolies.

Jim Cramer: Tech Can't Do it All Alone

Jim Cramer: Tech Can't Do it All Alone

Tech and retail gains aren't enough to lead markets to new highs.

Intermediate Trade: Johnson & Johnson

Intermediate Trade: Johnson & Johnson

JNJ is one of the best of breed of the pharmaceuticals sector.

Johnson & Johnson Announces Progress Toward Health For Humanity Goals

Johnson & Johnson Announces Progress Toward Health For Humanity Goals

Annual Health for Humanity Report Discloses Progress on Global Commitments and Highlights Key Achievements Toward Eradicating and Preventing Disease, Reimagining Care Delivery and Promoting Lifelong Health

Monday Madness: Let's Talk Stock Picks

Monday Madness: Let's Talk Stock Picks

Let's go over the top stories from Monday.

James Allison, Ph.D., Wins 2018 Dr. Paul Janssen Award For Biomedical Research

James Allison, Ph.D., Wins 2018 Dr. Paul Janssen Award For Biomedical Research

Johnson & Johnson Launches New Programs to Fuel Diverse Champions of Science

Good Job Growth, Low Inflation: Cramer's 'Mad Money' Recap (Friday 6/1/18)

Good Job Growth, Low Inflation: Cramer's 'Mad Money' Recap (Friday 6/1/18)

Jim Cramer says the market like this economy; he has your game plan for next week.

Knowledge Is Power in Buy & Sell Decisions

Knowledge Is Power in Buy & Sell Decisions

Johnson & Johnson is a premiere company, but the trick is knowing when to buy it.

Income Seeker: Use These 2 Dividend ETFs to Create a Good Mix of Income and Risk

Combining the lower-risk fund with a higher-risk one could make sense.

Tuesday's Market Sell-Off: The 52 Week Highs and Lows

Tuesday's Market Sell-Off: The 52 Week Highs and Lows

The market is sliding. Let's look at the top stocks that are trading at 52 week highs and 52 week lows.

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Jim Cramer says it's extremely important to buy stocks that are exactly right for you and your level of risk tolerance.

California Jury Delivers $25.75 Million Verdict In Asbestos Case Tying Johnson's Baby Powder To Mesothelioma

Simon Greenstone Panatier represents 66-year-old woman with deadly cancer

How to Play the Long Side of Johnson & Johnson

How to Play the Long Side of Johnson & Johnson

Shares of the healthcare giant pick up a quant rating upgrade as the charts suggest gains ahead.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APLE, DE, GRIF, IHT, JNJ, MFSF, MLI, NLS, SID, WYN Downgrades: AAME, CPB, NTES, SJR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Nike, Johnson & Johnson, Pure Storage: 'Mad Money' Lightning Round

Nike, Johnson & Johnson, Pure Storage: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Nike, Johnson & Johnson, Pure Storage, Gulfport Energy, Insperity, Cirrus Logic and more.

TheStreet Quant Rating: B- (Buy)